Objective 
Introduction

Community-acquired pneumonia (CAP) is a common and serious illness. Effective and efficient care of CAP has been a growing concern, and the 2005 European Respiratory Society guidelines have encouraged the implementation of clinical pathway (CP) care to ensure appropriate care for CAP patients (1). However, it's the frequency of CP use in studies have evaluated the effects of CP on time taken for attaining clinical stability and duration of total antibiotic administrations (intravenous plus oral)
. (12) . Intravenous administration of β-lactams (penicillin and cephalosporins) and macrolides is frequently used for initial empiric therapy, and switch therapy with these agents results in decreased serum levels compared to that during intravenous administration; this is known as 'step-down' therapy (12) . Conversely, most fluoroquinolones achieve comparable serum levels when administered intravenously or orally (1, 13) . Efficacy of sequential intravenous oral antibiotic therapy with a respiratory fluoroquinolone has been reported (14) , and its efficacy against drug-resistant pathogens has also been documented (15) . As β-lactam-and macrolideresistant pathogens have been increasing in Japan (16) , respiratory fluoroquinolones are expected to be more effective.
For selecting oral antibiotics for switch therapy, the 2001 American Thoracic Society (ATS) guidelines recommended that oral therapy should continue the spectrum of intravenous agents used if a specific pathogen is unidentified
However, usable intravenous respiratory fluoroquinolones
are not yet approved in Japan. Therefore, switching from an intravenous β-lactam plus a macrolide to an oral respiratory fluoroquinolone may prove effective. In order to limit the emergence of fluoroquinolone-resistant strains, use of respiratory fluoroquinolone should be limited (17) .
Our CP included switch therapy and followed the 2001 ATS guidelines. While selecting an oral antibiotic for switch therapy, our CP required the physician to use a respiratory fluoroquinolone in order to avoid 'step-down' therapy, when a specific pathogen was unidentified and the patient exhibited risk factors for drug-resistant pathogens. The objective of the present study was to investigate the use of CP and its implication for CAP treatment in a community hospital.
Methods
Design and study population
We conducted a retrospective cohort study of CAP 
Discussion
The primary finding of the present study is that CP implementation in a community hospital (shown in Fig. 1 (Table 5) . Thus, the shorter time taken to attain clinical stability in the CP group may suggest the usefulness of the treatment strategy of this CP in practice (Fig. 1) . In addition, the shorter time taken to attain clinical stability seemed to result in reduced LOS. As shown in Table 5 In non-CP group: pneumonia relapsed in 4 patients. One of these patients was included in the early failure and readmission or readministration of antibiotics. §Selected antibiotics for switch therapy were as follows: 1 patient received levofloxacin;
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menting CP. We speculate that the low proportion of CP implementation in the present study was caused by the difference in physicians' positive attitude towards CP implementation and selection of patients with better condition for CP application. In fact, patients with A-DROP score in the CP group had a tendency to shift towards lower scores than those in the non-CP group. Therefore, while evaluating the outcome measures, we considered that simple comparison of the two groups was inadequate, and classified the CAP patients on the basis of severity to evaluate the outcome measures between the groups. Previous studies showed that early switch and early discharge strategies, or adoption of CP for CAP, improved mortality and reduced LOS, cost, and duration of intravenous antibiotic treatment (8-10, 23, 24). We speculated the factors other than CP and early switch therapy that could lead to reduced LOS. The retrospective study by Frei et al revealed that guideline-concordant antibiotic therapy was associated with a shorter time to switch therapy, clinical stability, and LOS (3). Therefore, we evaluated the time taken to attain clinical stability. This CP included early switch therapy, in accordance with the 2001 ATS guidelines, and we found that time taken to attain clinical stability was significantly reduced in the mild and moderate classes without worsening of clinical outcomes
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another received moxifloxacin. ¶Initial empiric therapy failed early in these 2 patients; CP care was discontinued on day 3 and 4, and switch therapies were not performed. Causes of death were as follows: one patient suffered a relapse of pneumonia due to aspiration (day 44); another suffered acute exacerbation of interstitial pneumonia (day 20). (12, 25, 26 (27, 28 (19) . However, in the actual practice, the admission of patients with an A-DROP score of 0 may be often allowed because physicians take additional critical factors, which are not determined by A-DROP and include the ability to safely and reliably take oral medication and the availability of outpatient support resources, into the decision to hospitalize (27) .
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The present study has limitations. First, the study was not randomized and the generality of our findings is limited. Second, we included patients who received prolonged treatment even after improvement in condition, because the criterion for discontinuing antibiotic treatment after switch therapy was not determined. Third, our study showed more prolonged LOS compared to other reports (7, 9, 23 T a b l e 5 . Co mp a r i s o n o f L e n g t h o f Ho s p i t a l S t a y , Ho s p i t a l Ch a r g e s , T 
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F i g u r e 1 . Cl i n i c a l p a t h wa y f o r t h e t r e a t me n t o f CAP .
* E x c l u s i o n c r i t e r i a we r e a g e ( < 1 5 ) , a p p a r e n t a s p i r a t i o n , p l e u r i t i s a n d e mp y e ma , o b s t r u c t i v e p n e u mo n i a , a n d p r e g n a n c y . 
